Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Cancer Immunology Research|August 24, 2016
VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in MelanomaXinqi Wu, Anita Giobbie-Hurder, Xiaoyun Liao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancerMichael Atkins, Meredith Regan, David McDermott, et al.
Medical Oncology (Northwood, London, England)|February 8, 2011
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802Naomi B Haas, Xinyi Lin, Judith Manola, et al.
Cancer Treatment Reviews|July 26, 2014
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanomaDavid McDermott, Celeste Lebbé, F Stephen Hodi, et al.
Medical Oncology (Northwood, London, England)|February 21, 2009
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologiesJanice P Dutcher, Paul de Souza, David McDermott, et al.
Clinical Genitourinary Cancer|March 13, 2025
CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Stephanie A Berg, et al.
Immunotherapy|December 20, 2018
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanomaAhmad Tarhini, David McDermott, Apoorva Ambavane, et al.
Clinical Genitourinary Cancer|October 25, 2007
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinomaDaniel Cho, Sabina Signoretti, Sandra Dabora, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2010
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanomaJohn M Kirkwood, Paul Lorigan, Peter Hersey, et al.
Immunotherapy|September 4, 2018
Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysisAhmad Tarhini, Agnes Benedict, David McDermott, et al.
Pageof 6